Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share (TVRD)

Q: What does CUSIP 140755307 represent in this 13F holders report?

CUSIP 140755307 is the security identifier for TVRD - Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share used to aggregate holder disclosures.

Q: How many institutions held TVRD - Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share in Q3 2025?

64 institutional investors reported TVRD - Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share for Q3 2025. Use the holders table for investor-level position and value details.

CUSIP: 140755307

Q3 2025 13F Holders as of 30 Sep 2025

Type / Class: Equity / Common Stock, par value $0.001 per share
Shares outstanding: 9,470,889
Total 13F shares: 2,603,814
Share change: +679,986
Total reported value: $101,367,779
Put/Call ratio: 6.4%
Price per share: $38.97
Number of holders: 64
Value change: +$26,943,937
Number of buys: 42
Number of sells: 13

Quarterly Holders Quick Answers

What is CUSIP 140755307?
CUSIP 140755307 identifies TVRD - Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q4 2025
Previous quarter: Q2 2025

Recent filing periods for CUSIP 140755307:

Q1 2026 Q4 2025 Q3 2025 Q2 2025

Top shareholders of TVRD - Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Ronald A. DePinho	13D/G	—	6.7%	626,190	$24,413,770	-$6,035,311	30 Sep 2025	13D/G
Sporos Bioventures LLC	13D/G	—	9%	837,636	$19,544,812	$0	15 Apr 2025	13D/G
Slate Path Capital LP	13D/G 13F	Company	7.5%	704,118	$19,257,627	$0	30 Jun 2025	13D/G 13F
VANGUARD GROUP INC	13F	Company	4.2%	398,410	$9,294,905	—	30 Jun 2025	13F
CSL LTD	3/4/5	10%+ Owner	— class O/S missing	7,396,770	$9,024,059	—	09 Aug 2022	3/4/5
Vifor (International) Ltd	3/4/5 13D/G	10%+ Owner	2.2% from 13D/G	7,396,770	$9,024,059	—	20 Oct 2021	3/4/5 13D/G
Samuel D. Tweardy	13D/G	—	3.4%	315,658	$7,365,343	-$14,730,686	07 Jul 2025	13D/G
BlackRock, Inc.	13F	Company	2.8%	267,875	$6,249,524	—	30 Jun 2025	13F
Solas Tvardi Sidecar LLC	13D/G	—	8.1%	761,287	$4,050,047	$0	15 Apr 2025	13D/G
683 Capital Management, LLC	13F	Company	1.9%	176,030	$3,631,499	—	30 Jun 2025	13F
David J. Tweardy	13D/G	—	7%	652,398	$3,470,757	$0	15 Apr 2025	13D/G
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1.2%	112,138	$2,616,997	—	30 Jun 2025	13F
Shaheen Wirk	3/4/5	Director	— mixed-class rows	451,194 mixed-class rows	$2,225,966	—	17 Apr 2025	3/4/5
Wallace L. Hall Jr.	3/4/5	Director	— mixed-class rows	258,756 mixed-class rows	$1,250,632	—	17 Apr 2025	3/4/5
Chalmers Derek T.	3/4/5	President & CEO, Director	— class O/S missing	991,405	$1,209,514	—	07 Sep 2021	3/4/5
FARALLON CAPITAL MANAGEMENT LLC	13F	Company	0.46%	43,225	$1,008,439	—	30 Jun 2025	13F
STATE STREET CORP	13F	Company	0.44%	41,529	$968,872	—	30 Jun 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.33%	31,234	$728,689	—	30 Jun 2025	13F
NORTHERN TRUST CORP	13F	Company	0.32%	30,408	$709,419	—	30 Jun 2025	13F
UBS Group AG	13F	Company	0.31%	29,353	$684,806	—	30 Jun 2025	13F
MARSHALL WACE, LLP	13F	Company	0.26%	24,980	$582,784	—	30 Jun 2025	13F
Duncan Williams Asset Management, LLC	13F	Company	0.23%	21,830	$509,294	—	30 Jun 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.18%	17,085	$398,594	—	30 Jun 2025	13F
Martin Vogelbaum	3/4/5	Director	— mixed-class rows	801,007 mixed-class rows	$308,255	—	04 Jun 2024	3/4/5
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.13%	12,052	$281,173	—	30 Jun 2025	13F
Jeffrey L. Ives	3/4/5	Director	— mixed-class rows	393,485 mixed-class rows	$148,864	—	04 Jun 2024	3/4/5
Lisa von Moltke	3/4/5	Director	— mixed-class rows	378,009 mixed-class rows	$137,257	—	04 Jun 2024	3/4/5
BARCLAYS PLC	13F	Company	0.06%	5,789	$135,058	—	30 Jun 2025	13F
MORGAN STANLEY	13F	Company	0.05%	4,894	$114,178	—	30 Jun 2025	13F
Helen M. Boudreau	3/4/5	Director	— mixed-class rows	345,647 mixed-class rows	$112,985	—	04 Jun 2024	3/4/5
NEW YORK STATE COMMON RETIREMENT FUND	13F	Company	0.04%	4,000	$92,000	—	30 Jun 2025	13F
Frederique Ph.D. Menzaghi	3/4/5	CHIEF SCIENTIFIC OFF,SVP-R&D	— class O/S missing	167,247	$91,986	—	01 Feb 2024	3/4/5
Headlands Technologies LLC	13F	Company	0.04%	3,431	$80,045	—	30 Jun 2025	13F
RHUMBLINE ADVISERS	13F	Company	0.04%	3,411	$79,571	—	30 Jun 2025	13F
DEUTSCHE BANK AG\	13F	Company	0.03%	3,030	$70,690	—	30 Jun 2025	13F
Harrison M. Bains Jr.	3/4/5	Director	— mixed-class rows	102,399 mixed-class rows	$70,074	—	01 Jun 2023	3/4/5
Christopher Posner	3/4/5	PRESIDENT AND CEO, Director	— class O/S missing	13,109	$62,268	—	28 Feb 2025	3/4/5
WELLS FARGO & COMPANY/MN	13F	Company	0.03%	2,509	$58,535	—	30 Jun 2025	13F
Thomas Charles Reilly	3/4/5	Chief Financial Officer	— mixed-class rows	77,811 mixed-class rows	$46,129	—	03 Mar 2022	3/4/5
Joana Goncalves	3/4/5	CHIEF MEDICAL OFFICER	— class O/S missing	53,365	$44,293	—	05 Apr 2024	3/4/5
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	13F	Company	0.02%	1,863	$43,464	—	30 Jun 2025	13F
JPMORGAN CHASE & CO	13F	Company	0.02%	1,668	$38,914	—	30 Jun 2025	13F
Scott Terrillion	3/4/5	SEC'Y; CHIEF COMPLIANCE & G.C.	— class O/S missing	7,190	$34,224	—	28 Feb 2025	3/4/5
CITIGROUP INC	13F	Company	0.01%	1,152	$26,876	—	30 Jun 2025	13F
Arax Advisory Partners	13F	Company	0.01%	867	$20,228	—	30 Jun 2025	13F
Richard Makara	3/4/5	VP, Head of Accting;Controller	— class O/S missing	13,583	$16,571	—	15 Jun 2022	3/4/5
Ameritas Investment Partners, Inc.	13F	Company	0%	349	$8,142	—	30 Jun 2025	13F
Ryan D. Maynard	3/4/5	CHIEF FINANCIAL OFFICER	— mixed-class rows	94,500 mixed-class rows	$7,425	—	08 Feb 2024	3/4/5
Legal & General Group Plc	13F	Company	0%	310	$7,232	—	30 Jun 2025	13F
BNP PARIBAS FINANCIAL MARKETS	13F	Company	0%	300	$6,999	—	30 Jun 2025	13F

Institutional Holders of Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share (TVRD) as of Q3 2025

As of 30 Sep 2025, Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share (TVRD) was held by 64 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 2,603,814 shares. The largest 10 holders included Slate Path Capital LP, VANGUARD GROUP INC, BlackRock, Inc., 683 Capital Management, LLC, Vestal Point Capital, LP, GEODE CAPITAL MANAGEMENT, LLC, Invesco Ltd., FMR LLC, Parkman Healthcare Partners LLC, and STATE STREET CORP. This page lists 64 institutional shareholders reporting positions in this security for the Q3 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q3 2025 vs Q2 2025 Across Filers

Q2 2025 holders

Q3 2025 holders

Holder diff

Investor	Q2 2025 Shares	Q3 2025 Shares	Share Diff	Share Chg %	Q2 2025 Value $	Q3 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.